Navigation Links
Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer
Date:7/1/2009

PROVIDENCE, RI New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer. The study is published in the July edition of the journal Molecular Endocrinology. This new study by Edward Filardo, MD, and his research team further supports earlier published work by the group that linked the transmembrane receptor, GPR30/GPER-1, to specific estrogen binding, rapid estrogen signaling and breast cancer metastasis. "What is exciting about this new work," says Filardo, "is that it provides some insight into the influence of GPR30 at the cellular level. It shows that estrogen action through GPR30 allows for breast tumor cell survival, and not breast tumor cell proliferation." Prior studies by Filardo's group showed that estrogen acts through GPR30 to promote the rapid release of preformed growth factors that are tethered to the surface of breast cancer cells. Their latest study was conducted in an effort to better understand the mechanism by which GPR30 triggered the release of epidermal growth factor (EGF) polypeptides from the surface of breast cancer cells.

The investigator's found that the "growth factors" did not promote cellular growth, which by itself is not a novel finding. It has long been appreciated that EGF-related factors are also important in other cellular activities such as cellular survival. Filardo and the research team, however, found that estrogen action through GPR30 had a more profound effect on tumor cell survival. They found that GPR30 promoted the assembly of what is called a "provisional extracellular matrix" -- a crucial event in cellular survival. More specifically, they found that release of growth factor by GPR30 required the activation of a latent adhesion receptor (known as integrin 51).

Filardo says, "Activation of integrin 51 by GPR30 is a significant event because it provides a way for invading cells to gain hold once they metastasize to tissues distant to the primary breast cancer. This happens because activated integrin 51 can convert soluble plasma protein fibronectin into an insoluble cage. The breast cancer cells can use this to adapt to a new environment."

In general, about two-thirds of all breast cancer cases involve tumors that retain expression of estrogen receptors (ER). They are presumed to proliferate in response to estrogen produced by the patient. Consequently, patients with ER-positive tumors receive hormonal agents (known as ER antagonists) that act by blocking the proliferative effects of estrogen promoted by the ER. As a result, the capacity of breast cancers to grow is reduced. The development of new drugs targeting GPR30 may be an important step in controlling breast cancer because this newly appreciated estrogen receptor is not promoting estrogen-dependent growth but may be critical in promoting breast tumor cell survival.

Filardo says, "There has been a recent shift toward treating ER-positive breast tumor patients with aromatase inhibitors such as tamoxifen that block estrogen biosynthesis. The thought is that this is yet another way to prevent estrogen from acting as its sole receptor, the ER." He concludes, "The discovery that GPR30 represents yet another estrogen receptor with biological significance for breast cancer furthers the argument that aromatase inhibitors would effectively block estrogen action at both types of estrogen receptors."


'/>"/>

Contact: Nancy Cawley Jean
njean@lifespan.org
Lifespan
Source:Eurekalert

Related medicine news :

1. Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network
2. Dr. Juan Carlos Cobo Newly-Elected Chair of the Mutual Protection Trust Board of Trustees
3. Missouri Doctor, David Barbe, M.D., Newly Elected to AMA Board of Trustees
4. kidneySPA Introduces A Revolutionary Approach To Dialysis Treatment Newly Opened Facility Combines "Medical" Expertise with "Spa-Like" Experience
5. Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug
6. Newly Identified Compounds May Inhibit Strep Infection
7. Now we know what blocks the effects of a newly developed anticancer therapy
8. Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money
9. MAXANT Launches MediPort 3000, The Next-Generation of All-In-One Workstations, on Its Newly Designed Website
10. Discount Medical Supplies Superstore Announces Newly Updated Website: Easy Shopping, Hundreds of Top Brands
11. Walnuts and Fish Protect Against Heart Disease in Different Ways, According to Newly Published Loma Linda University Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... VisualSP has helped over 1.5 million SharePoint users learn the content management system ... Help System for SharePoint was at the farm level. Enterprises using SharePoint Online in ... The company recently released a modified version of the Help System, VisualSP for Site ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual American ... Diabetes Risk Test to find out if they are at risk for developing Type ... up the evening sky by programming the LAX pylons the color red. Downtown’s U.S. ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s ... technology to directly address the resolution to globally reduce the harmful use of ... compound of FDA and TTB approved ingredients that when infused into alcohol, renders ...
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid ... Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and ... regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... New York , March 29, 2017 /PRNewswire/ ... recently published a report, which provides an exhaustive ... to the study, nearly 242 companies are functional ... fragmented and competitive. With the leading companies, such ... Purdue Pharma LP, focusing aggressively on various marketing ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... drugs market to grow at a CAGR of 2.87% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
Breaking Medicine Technology: